EGFR mutations, especially in exons 19 and 21, are associated with tumor proliferation and responsiveness to tyrosine kinase inhibitors, making EGFR of therapeutic and prognostic relevance in SMs from NSCLC [8]. The gene discussed is EGFR; the disease is neoplasm.